Charles Schwab
KIN

Charles Schwab’s Kindred Biosciences, Inc. KIN Stock Holding History

Charles Schwab’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-18,803
Closed -$173K – 3584
2021
Q2 		$173K Sell
18,803
-77,623
-81% -$452K ﹤0.01% 3273
2021
Q1 		$480K Hold
96,426
– – ﹤0.01% 3091
2020
Q4 		$416K Hold
96,426
– – ﹤0.01% 3047
2020
Q3 		$414K Sell
96,426
-4,855
-5% -$20.3K ﹤0.01% 2928
2020
Q2 		$455K Buy
101,281
+4,326
+4% +$19.3K ﹤0.01% 2874
2020
Q1 		$388K Buy
96,955
+110
+0.1% +$934 ﹤0.01% 2798
2019
Q4 		$822K Buy
96,845
+9,902
+11% +$77.3K ﹤0.01% 2662
2019
Q3 		$596K Hold
86,943
– – ﹤0.01% 2734
2019
Q2 		$725K Buy
86,943
+7,742
+10% +$66.8K ﹤0.01% 2684
2019
Q1 		$727K Buy
79,201
+13,072
+20% +$133K ﹤0.01% 2648
2018
Q4 		$725K Hold
66,129
– – ﹤0.01% 2636
2018
Q3 		$923K Buy
66,129
+9,150
+16% +$124K ﹤0.01% 2652
2018
Q2 		$607K Buy
56,979
+14,879
+35% +$145K ﹤0.01% 2743
2018
Q1 		$365K Hold
42,100
– – ﹤0.01% 2820
2017
Q4 		$398K Buy
42,100
+6,600
+19% +$51.6K ﹤0.01% 2788
2017
Q3 		$279K Hold
35,500
– – ﹤0.01% 2907
2017
Q2 		$306K Buy
+35,500
New +$255K ﹤0.01% 2858
2015
Q3 		– Sell
-15,620
Closed -$107K – 3103
2015
Q2 		$107K Sell
15,620
-11,670
-43% -$82.8K ﹤0.01% 3044
2015
Q1 		$195K Buy
27,290
+14,390
+112% +$99.2K ﹤0.01% 2950
2014
Q4 		$97K Sell
12,900
-7,207
-36% -$61.1K ﹤0.01% 3065
2014
Q3 		$186K Buy
20,107
+403
+2% +$5.45K ﹤0.01% 2969
2014
Q2 		$368K Buy
+19,704
New +$335K ﹤0.01% 2764

Other funds holding KIN

CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

Charles Schwab's KIN Position: Q3 2021 in Review

Charles Schwab sold out of Kindred Biosciences, Inc. (KIN) in Q3 2021, closing a stake of 18,803 shares — an estimated $173K sold.

Charles Schwab first reported a position in KIN in Q2 2014 and held it in 22 quarters. The position peaked at $923K in Q3 2018. 1 fund tracked by Wall St. Rank holds KIN as of Q3 2021.

  • Charles Schwab reported no remaining Kindred Biosciences, Inc. position as of Q3 2021 after selling out during the quarter.
  • Charles Schwab sold 18,803 Kindred Biosciences, Inc. shares in Q3 2021, an estimated $173K.
  • Charles Schwab first reported a position in Kindred Biosciences, Inc. in Q2 2014 and held it in 22 quarters.
  • Charles Schwab's Kindred Biosciences, Inc. position peaked at $923K in Q3 2018.
  • 1 fund tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2021.

Based on Charles Schwab's 13F filing for Q3 2021, filed 16 Nov 2021.